Literature DB >> 23164716

Carboplatin delays mammary cancer 4T1 growth in mice.

Cristina Maria de Souza1, Conrado de Oliveira Gamba, Cecília Bonolo de Campos, Miriam Teresa Paz Lopes, Mônica Alves Neves Diniz Ferreira, Silvia Passos Andrade, Geovanni Dantas Cassali.   

Abstract

Carboplatin is commonly used to treat a variety of tumors. We investigated the effects of carboplatin (100mg/kg) in the development and metastatic dissemination of the 4T1 mice mammary carcinoma. Carboplatin was able to reduce tumor volume and the number of lung metastases in 50% compared to the control animals. Mitotic and apoptotic indices were also decreased by the treatment. Assessment of the vascularization of the tumors revealed a significant decrease in blood vessel formation by carboplatin. A decrease in nuclear positivity of CDC47 and cyclin D1 was observed in the group treated with carboplatin when compared to the control group. Positivity for p53 was observed in the control group (2/28; 5%) and the treated group (5/71; 4%). Carboplatin has been demonstrated to be an efficient regulator of 4T1MMT growth and dissemination. The action of this chemotherapeutic agent seems to be related to the induction of apoptosis and inhibition of angiogenesis and cell proliferation.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23164716     DOI: 10.1016/j.prp.2012.10.003

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  5 in total

1.  C(3)1-TAg in C57BL/6 J background as a model to study mammary tumor development.

Authors:  Isadora F G Sena; Beatriz G S Rocha; Caroline C Picoli; Gabryella S P Santos; Alinne C Costa; Bryan O P Gonçalves; Ana Paula V Garcia; Maryam Soltani-Asl; Leda M C Coimbra-Campos; Walison N Silva; Pedro A C Costa; Mauro C X Pinto; Jaime H Amorim; Vasco A C Azevedo; Rodrigo R Resende; Debora Heller; Geovanni D Cassali; Akiva Mintz; Alexander Birbrair
Journal:  Histochem Cell Biol       Date:  2021-05-18       Impact factor: 4.304

2.  Carboplatin activates the cGAS-STING pathway by upregulating the TREX-1 (three prime repair exonuclease 1) expression in human melanoma.

Authors:  Zhourui Ma; Qianwei Xiong; Hongliang Xia; Wei Liu; Shu Dai; Shizhong Cai; Zhenhong Zhu; Xiangming Yan
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

3.  Platinum Chemotherapy Induces Lymphangiogenesis in Cancerous and Healthy Tissues That Can be Prevented With Adjuvant Anti-VEGFR3 Therapy.

Authors:  Alexandra R Harris; Savieay Esparza; Mohammad S Azimi; Robert Cornelison; Francesca N Azar; Danielle C Llaneza; Maura Belanger; Alexander Mathew; Svyatoslav Tkachenko; Matthew J Perez; Claire Buchta Rosean; Raegan R Bostic; R Chase Cornelison; Kinsley M Tate; Shayn M Peirce-Cottler; Cherie Paquette; Anne Mills; Charles N Landen; Jeff Saucerman; Patrick M Dillon; Rebecca R Pompano; Melanie A Rutkowski; Jennifer M Munson
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 5.738

4.  Anacardic Acids from Amphipterygium adstringens Confer Cytoprotection against 5-Fluorouracil and Carboplatin Induced Blood Cell Toxicity While Increasing Antitumoral Activity and Survival in an Animal Model of Breast Cancer.

Authors:  Jairo Galot-Linaldi; Karla M Hernández-Sánchez; Elizabet Estrada-Muñiz; Libia Vega
Journal:  Molecules       Date:  2021-05-28       Impact factor: 4.411

5.  Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.

Authors:  Meizhuo Gao; Tie Wang; Litong Ji; Shuping Bai; Lining Tian; Hongjiang Song
Journal:  Front Immunol       Date:  2020-03-05       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.